Clinical Pathology Laboratories, Inc.

Clinical Pathology Laboratories, Inc. specializes in providing diagnostic laboratory testing and services to enhance healthcare decision-making for practitioners and patients alike. Clinical Pathology Laboratories, Inc. offers laboratory testing and diagnostic services, founded in 1948 in Austin, Texas, US.

The company was acquired by Sonic Healthcare in October 2005 from Summit Partners. The CEO is Mark Silberman. Clinical Pathology Laboratories (CPL) provides a comprehensive range of laboratory testing and diagnostic services focused on meeting the needs of healthcare practitioners and patients. Their core offerings include guidance-driven laboratory testing and screening services that empower patients to make informed health decisions.

Key products include their SonicMyAccess™ portal, which allows patients to access and understand their test results easily. By serving clinicians and patients across multiple healthcare segments, CPL emphasizes quality and accessibility, ensuring that laboratory services are available to diverse populations regardless of age, income, or insurance coverage. The company operates over 200 locations, primarily in Texas, while also extending its services to various markets across the United States through partnerships with healthcare providers. CPL operates on a revenue model that encompasses a mix of direct-to-consumer transactions and B2B partnerships with healthcare providers.

The company generates revenue through its laboratory testing services, which are typically billed per test or as part of comprehensive diagnostic packages. Clients range from individual patients seeking testing to healthcare facilities and clinicians requiring extensive laboratory services. Specific pricing details for individual tests or services are structured to reflect the complexity and type of testing provided, ensuring that both patients and practitioners receive tailored solutions. By leveraging its established network and expertise in the field, CPL aims to sustain a steady flow of transactions, enhancing its operational efficiency and service delivery.

While specific upcoming products or services have not been detailed, the company likely seeks to leverage its existing infrastructure to solidify its presence in the diagnostic laboratory market. Expansion into new markets is anticipated, although specifics on targeted regions and timelines are not outlined. The funds from the most recent round, a Trade Sale amounting to USD 312. 00 mn, will likely support initiatives to enhance operational capabilities and service offerings.